| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?
|
Figlin, R.A.
|
|
|
29 |
2 |
p. 324-331
|
article
|
| 2 |
A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor
|
Leroy, L.
|
|
|
29 |
2 |
p. 514-515
|
article
|
| 3 |
Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study
|
Pettersson, A.
|
|
|
29 |
2 |
p. 377-385
|
article
|
| 4 |
Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer
|
Yang, D.D.
|
|
|
29 |
2 |
p. 386-391
|
article
|
| 5 |
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
|
Tai, W.M.
|
|
|
29 |
2 |
p. 526
|
article
|
| 6 |
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone
|
Wang, L.
|
|
|
29 |
2 |
p. 352-360
|
article
|
| 7 |
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
|
Zhang, L.
|
|
|
29 |
2 |
p. 452-458
|
article
|
| 8 |
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|
Ferrucci, P.F.
|
|
|
29 |
2 |
p. 524
|
article
|
| 9 |
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
|
Cardoso, F.
|
|
|
29 |
2 |
p. 405-417
|
article
|
| 10 |
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
|
Lee, R.J.
|
|
|
29 |
2 |
p. 490-496
|
article
|
| 11 |
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
|
de Boer, S.M.
|
|
|
29 |
2 |
p. 424-430
|
article
|
| 12 |
Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer
|
Guihot, A.
|
|
|
29 |
2 |
p. 517-518
|
article
|
| 13 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
|
Sestak, I.
|
|
|
29 |
2 |
p. 504-509
|
article
|
| 14 |
Editorial board
|
|
|
|
29 |
2 |
p. ii-iii
|
article
|
| 15 |
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients
|
Trédan, O.
|
|
|
29 |
2 |
p. 523
|
article
|
| 16 |
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia
|
Ladetto, M.
|
|
|
29 |
2 |
p. 525
|
article
|
| 17 |
Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors
|
Michot, J.-M.
|
|
|
29 |
2 |
p. 518-520
|
article
|
| 18 |
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial
|
Abad, A.
|
|
|
29 |
2 |
p. 439-444
|
article
|
| 19 |
Goserelin does not preserve ovarian function against chemotherapy-induced damage
|
Oktay, K.
|
|
|
29 |
2 |
p. 512-513
|
article
|
| 20 |
Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas
|
Udager, A.M.
|
|
|
29 |
2 |
p. 466-471
|
article
|
| 21 |
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
|
Bamias, A.
|
|
|
29 |
2 |
p. 361-369
|
article
|
| 22 |
Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial
|
Noordman, B.J.
|
|
|
29 |
2 |
p. 445-451
|
article
|
| 23 |
Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium
|
Ordóñez-Mena, J.M.
|
|
|
29 |
2 |
p. 472-483
|
article
|
| 24 |
Improved survival in metastatic germ-cell cancer
|
Fankhauser, C.D.
|
|
|
29 |
2 |
p. 347-351
|
article
|
| 25 |
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
|
Yang, M.
|
|
|
29 |
2 |
p. 311-323
|
article
|
| 26 |
Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B
|
Lin, G.
|
|
|
29 |
2 |
p. 516-517
|
article
|
| 27 |
Male breast cancer: pink ribbon blues
|
Francis, P.A.
|
|
|
29 |
2 |
p. 292-293
|
article
|
| 28 |
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors
|
Albany, C.
|
|
|
29 |
2 |
p. 341-346
|
article
|
| 29 |
Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis
|
McTyre, E.
|
|
|
29 |
2 |
p. 497-503
|
article
|
| 30 |
New antiemetics: facing the current challenge
|
Scotté, F.
|
|
|
29 |
2 |
p. 295-296
|
article
|
| 31 |
Nivolumab-associated bone marrow necrosis
|
Hilal, T.
|
|
|
29 |
2 |
p. 513-514
|
article
|
| 32 |
Outcome prediction in patients with localized soft tissue sarcoma: which tool is the best?
|
Kasper, B.
|
|
|
29 |
2 |
p. 297-298
|
article
|
| 33 |
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer
|
Provencher, D.M.
|
|
|
29 |
2 |
p. 431-438
|
article
|
| 34 |
Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?
|
Blinman, P.L.
|
|
|
29 |
2 |
p. 370-376
|
article
|
| 35 |
Pharmacogenomics: time to rethink its role in precision medicine
|
Willis, J.A.
|
|
|
29 |
2 |
p. 293-295
|
article
|
| 36 |
Prostate cancers that ‘Wnt’ respond to abiraterone
|
Linch, M.
|
|
|
29 |
2 |
p. 290-292
|
article
|
| 37 |
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
|
Kordbacheh, T.
|
|
|
29 |
2 |
p. 301-310
|
article
|
| 38 |
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial
|
Ek, L.
|
|
|
29 |
2 |
p. 398-404
|
article
|
| 39 |
Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302
|
Cella, D.
|
|
|
29 |
2 |
p. 392-397
|
article
|
| 40 |
Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
|
Cherny, N.I.
|
|
|
29 |
2 |
p. 521-522
|
article
|
| 41 |
Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas
|
Karmali, R.
|
|
|
29 |
2 |
p. 332-340
|
article
|
| 42 |
Table of Contents
|
|
|
|
29 |
2 |
p. iv-vii
|
article
|
| 43 |
Ten thousand attentive hours, rapid learning, dissemination of knowledge and the future of experience-based care in germ-cell tumors
|
Nichols, C.
|
|
|
29 |
2 |
p. 289-290
|
article
|
| 44 |
The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma
|
Bertucci, F.
|
|
|
29 |
2 |
p. 459-465
|
article
|
| 45 |
The predictive value of interim FDG-PET in early-stage Hodgkin lymphoma is not well established
|
Adams, H.J.A.
|
|
|
29 |
2 |
p. 510-512
|
article
|
| 46 |
Toxicity adjustment in the ESMO-MCBS: a gestalt approach?
|
Del Paggio, J.C.
|
|
|
29 |
2 |
p. 520-521
|
article
|
| 47 |
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy
|
Boffetta, P.
|
|
|
29 |
2 |
p. 484-489
|
article
|
| 48 |
Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board
|
Somashekhar, S.P.
|
|
|
29 |
2 |
p. 418-423
|
article
|
| 49 |
Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it
|
Prasad, V.
|
|
|
29 |
2 |
p. 299-301
|
article
|
Journal description